CEO & Chairman, 10% Owner of Emergent BioSolutions Inc. (EBS) Fuad El-hibri sells 15,000 shares of EBS on 08/11/2009 at an average price of $16.78 a share.
EMERGENT BIOSULUTIONS INC. is a leading biopharmaceutical company dedicated to one simple mission – to protect life. EBS develops manufactures and commercializes vaccines and therapeutics that assist the body\’s immune system to prevent or treat disease. Their products target infectious diseases and other medical conditions that have resulted in significant unmet or underserved public health needs. Their marketed product BioThrax? (Anthrax Vaccine Adsorbed) is the only vaccine approved by the U.S. Food and Drug Administration for the prevention of anthrax infection. Emergent BioSolutions Inc. has a market cap of $511.8 million; its shares were traded at around $16.91 with a P/E ratio of 13.1 and P/S ratio of 2.8.
Related posts:
- Emergent Biosolutions El-Hibri Fuad El-Hibri has filed an intention with the SEC to...
- Fuad El-Hibri Yale Health Care Advisory Board Mr. Fuad El-Hibri has served as chief executive officer and...
- Fuad El-Hibri on AOL Money For commercial markets, Emergent is working on therapies and...
Related posts brought to you by Yet Another Related Posts Plugin.
